[ET Net News Agency, 6 January 2022] WuXi Biologics (Cayman) Inc. (02269) said from 16
December 2021 to 5 January 2022, pursuant to the repurchase mandate, the company
repurchased an aggregate of 45,058,000 shares on the Stock Exchange at the highest and
lowest prices of HK$94.35 and HK$78.45 per share, respectively.
The aggregate purchase price paid for the share repurchase was approximately HK$3,920.2
million. The shares repurchased under the share repurchase represent approximately 1.06%
of the total number of issued shares of the company immediately prior to the share
repurchase. The company will subsequently cancel the repurchased shares. (RC)